BullishAgent BullishAgent Filings Economic Earnings Ratings IPOs Insiders Institutional ETFs Funds Screener
Sign in Register

IMDX

Insight Molecular Diagnostics Inc. NASDAQ Listed Dec 30, 2015
Healthcare ·Biotechnology ·US · imdxinc.com
$4.96
Mkt Cap $133.1M
52w Low $2.33 42.6% of range 52w High $8.51
50d MA $4.23 200d MA $4.75
P/E (TTM) -2.5x
EV/EBITDA -7.8x
P/B
Debt/Equity -0.1x
ROE 159.6%
P/FCF -9.0x
RSI (14)
ATR (14)
Beta 1.53
50d MA $4.23
200d MA $4.75
Avg Volume 222.4K
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
SIC Code
2835
CIK (SEC)
Phone
949 409 7600
15 Cushing · Nashville, TN 92618 · US
Data updated apr 25, 2026 3:16pm · Source: massive.com